Antioxidant supplements and cognition in Multiple Sclerosis: a systematic review
Journal Title: Neurology Letters - Year 2022, Vol 1, Issue 2
Abstract
Background: Cognitive dysfunction is a debilitating characteristic of multiple sclerosis (MS) that affects approximately 60% of patients. To date, the only effective treatments for cognitive decline are cognitive rehabilitation and exercise training. While previous studies reported the beneficial effect of antioxidants on MS patients, several other studies investigated the effect of antioxidant supplements on the cognitive performance of MS patients. We aimed to conduct a systematic review to examine whether there is an association between antioxidants supplements and cognitive performance in MS patients.Methods: We searched PubMed, Embase, Scopus, and Web of Science for the identification of relevant studies in November 2021. We included control trials, cohort, case-control, and cross-sectional studies which showed the effect of any type of antioxidants on cognitive performance in MS patients.Results: After screening 12 papers were included in our study. Our review included three studies that examined the effect of ginkgo Biloba on cognitive performance, two examined the Mediterranean diet, and remained studies each investigated the vitamin A, Omega 5, Omega 3, estriol, epigallocatechin-3-gallate (EGCG), Boswellia papyrifera, and paleolithic diet. Overall, it seems that there were no benefits of antioxidant administration on cognitive performance in MS patients.
Authors and Affiliations
Fardin Nabizadeh, Fatemeh Sodeifian, Ali Ghaderi, Amir Mohammad Sharafi, Mohammad Balabandian
Keywords
Related Articles
- EP ID EP711700
- DOI 10.52547/NL.1.2.48
- Views 82
- Downloads 0
Antioxidant supplements and cognition in Multiple Sclerosis: a systematic review
Background: Cognitive dysfunction is a debilitating characteristic of multiple sclerosis (MS) that affects approximately 60% of patients. To date, the only effective treatments for cognitive decline are cognitive rehabil...
Neurology Letters is born!
On behalf of our editorial board, editorial team, authors, reviewers, and supporting institutions – we warmly welcome you to the first issue of the Neurology Letters. This is the official journal of the Neurology departm...
Role of Biomaterials in treatment of Alzheimer’s disease: A literature review
Currently, five medications have been approved by the FDA to treat Alzheimer's disease (AD); Donepezil, which is used at all stages of AD, galantamine, and rivastigmine for mild to moderate stages, and Memantine and a co...
Association between infection with Chlamydia pneumonia and cerebral noncardioembolic ischemic stroke
Introduction: Stroke is the third most common cause of mortality and the most common disability disorder among adults. We aimed to study the relationship between Chlamydia pneumonia infection and non-cardio Ambulatory is...
What should we do to reduce the complications of Deep brain stimulation in Parkinson's disease?
Parkinson's Disease (PD) is one of the most common neurodegenerative disorders. Recently, Deep Brain Stimulation (DBS) was proposed as a potential therapeutic approach for PD patients. This procedure has side effects tha...